...
首页> 外文期刊>BMC Health Services Research >Use of prothrombin complex concentrate in warfarin anticoagulation reversal in the emergency department: a quality improvement study of administration delays
【24h】

Use of prothrombin complex concentrate in warfarin anticoagulation reversal in the emergency department: a quality improvement study of administration delays

机译:凝血酶原复合物浓缩物在急诊科华法林抗凝逆转中的应用:行政延误的质量改善研究

获取原文
           

摘要

Background Quick reversal of warfarin anticoagulation is important in life threatening bleeding. The aim of this study is to improve the administration delay when using Prothrombin Complex Concentrate (PCC) for the emergent reversal of warfarin anticoagulation in the emergency department. Methods An audit and feedback quality improvement project was conducted in three phases: a retrospective audit phase, an analysis and feedback phase and prospective evaluation phase. The charts of all eligible patients in a single Emergency Department (ED) in Québec, Canada, who received PCC since the introduction of this product in 2009 until October 31, 2011, were retrospectively audited. The administration delay of PCC was calculated from the time of prescription to the time of administration. With the data, we determined where improvements could be attained, and jointly with all stakeholders in the ED and the blood bank, we created an action plan to ensure the timely administration of PCC. The action plan was then implemented and a six-month prospective evaluation study was conducted to determine any improvement. Results Seventy-seven charts were reviewed in the retrospective chart audit. The mean administration delay was 73.6?minutes (STD [34.1]) with a median of 70.0?minutes (25–75% IQR [45.0–95.0]). We found that this delay was principally due to the following barriers: communication problems between the ED and the blood bank as well as delivery inefficiencies. An action plan that involved a flowchart to remind all clinicians how to order PCC and a new delivery method from the blood bank to the ED were developed. During the 6?months following the implementation of our action plan, 39 patients received PCC and the mean administration time decreased to 33.2?minutes (STD [14.2])( p Conclusion By implementing an action plan comprising of a flowchart and a new delivery process, this audit and feedback quality improvement project reduced the administration time of PCC by more than half. Future studies to measure the impact of a similar audit and feedback process involving an action plan in other centers should be conducted before this type of quality improvement process is implemented on wider scale.
机译:背景华法林抗凝剂的快速逆转在威胁生命的出血中很重要。这项研究的目的是改善在急诊科中使用凝血酶原复合浓缩液(PCC)紧急逆转华法林抗凝治疗时的给药延迟。方法审核和反馈质量改进项目分为三个阶段:回顾性审核阶段,分析和反馈阶段以及预期评估阶段。自2009年推出该产品以来至2011年10月31日,在加拿大魁北克的单个急诊科(ED)中接受PCC的所有合格患者的病历表均经过回顾性审核。从处方时间到给药时间计算PCC的给药延迟。利用这些数据,我们确定了可以改进的地方,并与ED和血库中的所有利益相关者共同制定了一项行动计划,以确保PCC的及时管理。然后执行了该行动计划,并进行了为期六个月的前瞻性评估研究,以确定是否有任何改进。结果回顾性图表审核中检查了77个图表。平均给药延迟为73.6分钟(STD [34.1]),中位数为70.0分钟(25-75%IQR [45.0-95.0])。我们发现这种延迟主要是由于以下障碍:ED与血库之间的通信问题以及输送效率低下。制定了包括提醒所有临床医生如何订购PCC的流程图的行动计划,以及从血库到ED的新分娩方法。在实施我们的行动计划后的6个月内,有39例患者接受了PCC,平均给药时间降至33.2分钟(STD [14.2])(p结论)通过实施包括流程图和新的分娩流程的行动计划,此审核和反馈质量改进项目将PCC的管理时间减少了一半以上,因此,在进行此类质量改进过程之前,应进行进一步的研究以评估涉及其他中心的行动计划的类似审核和反馈过程的影响大规模实施。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号